[1]
|
L. Christa, L. Thuillier, A. Munier and J. L. Perignon, “Salvage of 5’-Deoxy-methylthioadenosine into Purines and Methionine by Lymphoid Cells and Inhibition of Cell Proliferation,” Biochimica et Biophysica Acta, Vol. 803, No. 1-2, 1984, pp. 7-10.
doi:10.1016/0167-4889(84)90048-X
|
[2]
|
A. E. Pegg and H. G. Williams-Ashman, “Phosphate-Stimulated Breakdown of 5’-Methylthioadenosine by Rat Ventral Prostate,” Biochemical Journal, Vol. 115, 1969, pp. 241-247.
|
[3]
|
P. S. Backlund Jr. and R. A. Smith, “Methionine Synthesis from 5’-Methylthioadenosine in Rat Liver,” Journal of Biological Chemistry, Vol. 256, 1981, pp. 1533-1535.
|
[4]
|
T. W. Stone and H. A. Simmonds, “Purines: Basic and Clinical Aspects,” Kluwer Academic Publishers, Dordrecht, 1991. doi:10.1007/978-94-011-3911-3
|
[5]
|
N. Kamatani and D. A. Carson, “Dependence of Adenine Production upon Polyamine Synthesis in Cultured Human Lymphoblasts,” Biochim Biophys Acta, Vol. 675, 1981, pp. 344-350.
|
[6]
|
A. L. Subhi, P. Diegelman, C. W. Porter, B. Tang, Z. J. Lu, G. D. Markham and W. D. Kruger, “Methylthioa-denosine Phosphorylase Regulates Ornithine Decarboxylase by Production of Downstream Metabolites,” Journal of Biological Chemistry, Vol. 278, 2003, pp. 49868-49873.
doi:10.1074/jbc.M308451200
|
[7]
|
A. Batova, M. B. Diccianni, T. Nobori, T. Vu, J. Yu, L. Bridgeman and A. L. Yu, “Frequent Deletion in the Methylthioadenosine Phosphorylase Gene in T-Cell Acute Lymphoblastic Leukemia: Strategies for Enzyme-Targeted Therapy,” Blood, Vol. 88, 1996, pp. 3083-3090.
|
[8]
|
T. Nobori, J. G. Karras, F. Della Ragione, T. A. Waltz, P. P. Chen and D. A. Carson, “Absence of Methylthioa-denosine Phosphorylase in Human Gliomas,” Cancer Research, Vol. 51, 1991, pp. 3193-3197.
|
[9]
|
T. Nobori, K. Takabayashi, P. Tran, L. Orvis, A. Batova, A. L. Yu and D. A. Carson, “Genomic Cloning of Methylthioadenosine Phosphorylase: A Purine Metabolic Enzyme Deficient in Multiple Different Cancers,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 93, No. 12, 1996, pp. 6203-6208. doi:10.1073/pnas.93.12.6203
|
[10]
|
A. Batova, M. B. Diccianni, M. Omura-Minamisawa, J. Yu, C. J. Carrera, L. J. Bridgeman, F. H. Kung, J. Pullen, M. D. Amylon and A. L. Yu, “Use of Alanosine as a Methylthioadenosine Phosphorylase-Selective Therapy for T-Cell Acute Lymphoblastic Leukemia in Vitro,” Cancer Research, Vol. 59, 1999, pp. 1492-1497.
|
[11]
|
Z. H. Chen, O. I. Olopade and T. M. Savarese, “Expression of Methylthioadenosine Phosphorylase cDNA in p16-, MTAP-Malignant Cells: Restoration of Methylthioadenosine Phosphorylase-Dependent Salvage Pathways and Alterations of Sensitivity to Inhibitors of Purine De Novo Synthesis,” Molecular Pharmacology, Vol. 52, 1997, pp. 903-911.
|
[12]
|
A. Batova, H. Cottam, J. Yu, M. B. Diccianni, C. J. Carrera and A. L. Yu, “EFA (9-Beta-D-erythrofuranosyladenine) Is an Effective Salvage Agent for Methylthioadenosine Phosphorylase-Selective Therapy of T-Cell Acute Lymphoblastic Leukemia with L-Alanosine,” Blood, Vol. 107, No. 3, 2006, pp. 898-903.
doi:10.1182/blood-2005-06-2430
|
[13]
|
C. Rago, B. Vogelstein and F. Bunz, “Genetic Knockouts and Knockins in Human Somatic Cells,” Nature Protocols, Vol. 2, 2007, pp. 2734-2746.
doi:10.1038/nprot.2007.408
|
[14]
|
S. Swift, J. Lorens, P. Achacoso and G. P. Nolan, “Rapid Production of Retroviruses for Efficient Gene Delivery to Mammalian Cells Using 293T Cell-Based Systems,” Current Protocols in Immunology, 2001, Unit 10.17C.
|
[15]
|
P. J. Casey and J. M. Lowenstein, “Inhibition of Adenylosuccinate Lyase by L-Alanosyl-5-aminoimidazole-4-carboxylic Acid Ribonucleotide (Alanosyl-Aicor),” Biochemical Pharmacology, Vol. 36, No. 5, 1987, pp. 705-709. doi:10.1016/0006-2952(87)90722-2
|
[16]
|
A. K. Tyagi and D. A. Cooney, “Identification of the Antimetabolite of L-Alanosine, L-Alanosyl-5-amino-4-imidazole-carboxylic Acid Ribonucleotide, in Tumors and Assessment of Its Inhibition of Adenylosuccinate Synthetase,” Cancer Research, Vol. 40, 1980, pp. 4390-4397.
|
[17]
|
C. H. Takimoto, “New Antifolates: Pharmacology and Clinical Applications,” Oncologist, Vol. 1, 1996, pp. 68-81.
|
[18]
|
S. Coulthard and L. Hogarth, “The Thiopurines: An Update,” Investigational New Drugs, Vol. 23, No. 6, 2005, pp. 523-532. doi:10.1007/s10637-005-4020-8
|
[19]
|
N. Kamatani, W. A. Nelson-Rees and D. A. Carson, “Selective Killing of Human Malignant Cell Lines Deficient in Methylthioadenosine Phosphorylase, a Purine Metabolic Enzyme,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 78, No. 2, 1981, pp. 1219-1223. doi:10.1073/pnas.78.2.1219
|
[20]
|
G. M. Dosik, D. Stewart, M. Valdivieso, M. A. Burgess and G. P. Bodey, “Phase I Study of L-Alanosine Using a Daily x 3 Schedule,” Cancer Treatment Reports, Vol. 66, 1982, pp. 73-76.
|
[21]
|
H. L. Kindler, H. A. Burris, A. B. Sandler and I. A. Oliff, “A Phase II Multicenter Study of L-Alanosine, a Potent Inhibitor of Adenine Biosynthesis, in Patients with MTAP-Deficient Cancer,” Investigational New Drugs, Vol. 27, No. 1, 2009, pp. 75-81. doi:10.1007/s10637-008-9160-1
|
[22]
|
R. Munshi, A. S. Clanachan and H. P. Baer, “5’-Deoxy-5’-methylthioadenosine: A Nucleoside Which Differentiates between Adenosine Receptor Types,” Biochemical Pharmacology, Vol. 37, No. 10, 1988, pp. 2085-2089. doi:10.1016/0006-2952(88)90560-6
|
[23]
|
R. A. Olsson, E. M. Khouri, J. L. Bedynek Jr. and J. McLean, “Coronary Vasoactivity of Adenosine in the Conscious Dog,” Circulation Research, Vol. 45, 1979, pp. 468-478.
|
[24]
|
M. K. Riscoe and A. J. Ferro, “5-Methylthioribose. Its effects and Function in Mammalian Cells,” Journal of Biological Chemistry, Vol. 259, 1984, pp. 5465-5471.
|
[25]
|
A. K. Tyagi, D. C. Thake, E. McGee and D. A. Cooney, “Determinants of the Toxicity of L-Alanosine to Various Organs of the Mouse,” Toxicology, Vol. 21, No. 1, 1981, pp. 59-69. doi:10.1016/0300-483X(81)90016-0
|
[26]
|
J. Yu, A. Batova, L. Shao, C. J. Carrera and A. L. Yu, “Presence of Methylthioadenosine Phosphorylase (MTAP) in Hematopoietic Stem/Progenitor Cells: Its Therapeutic Implication for MTAP (-) Malignancies,” Clinical Cancer Research, Vol. 3, 1997, pp. 433-438.
|